期刊文献+

HPLC-CAD法测定6-乙基鹅去氧胆酸起始物料中有关物质 被引量:2

Determination of Related Substances in the Starting Material of 6-Ethylchenodeoxycholic Acid by HPLC-CAD
下载PDF
导出
摘要 目的:使用电喷雾检测器建立6-乙基鹅去氧胆酸起始物料的有关物质检测方法。方法:采用Waters XBridge Shield RP18(150 mm×4.6 mm,3.5μm)色谱柱,以0.05%三氟乙酸水溶液为流动相A,以乙腈为流动相B,梯度洗脱,流速为1.4 mL·min-1,柱温为35℃,电喷雾检测器(雾化温度:35℃)。结果:本品主峰与相邻杂质分离良好,在质量浓度0.5~15μg·mL^(-1)范围内线性关系良好,r=0.999,定量限为13.2 ng,检测限为5.3 ng,杂质重复性考察结果RSD均小于2%(n=6)。结论:方法精密度好、准确度高,可用于本品的有关物质检测。 Objective:To establish an method for the determination of related substances in the starting material of 6-ethylchenodeoxycholic acid by Charged Aerosol Detection(CAD).Methods:Waters XBridge Shield RP18 column(150 mm×4.6 mm,3.5μm)was used,0.05%Trifluoroacetic acid in water was used as mobile phase A,with Acetonitrile as mobile phase B in a gradient elution.The flow rate was 1.4 mL·min-1,column temperature was 35℃,CAD was used with atomization temperature 35℃.Results:The main substance and its impurities could be well separated.A good linear was obtained between ranges form 0.5μg·mL^(-1) to 15μg·mL^(-1) with Correlation coefficient 0.999.The limit of quantification was 13.2 ng,the limit of detection was 5.3 ng,and the RSD(n=6)of the impurity repeatability was less than 2%.Conclusion:The method has good precision and high accuracy,and can be used for the detection of related substances in the starting material of 6-ethylchenodeoxycholic acid.
作者 王恩 兰公剑 万国盛 林萍 秦玲萍 Wang En;Lan Gongjian;Wan Guosheng;Lin Ping;Qin Lingping(Nanjing Chia Tai Tianqing Pharmaceutical Co.,Ltd.,Nanjing 210046,China)
出处 《山东化工》 CAS 2021年第19期142-144,共3页 Shandong Chemical Industry
关键词 6-乙基鹅去氧胆酸起始物料 有关物质 高效液相色谱仪联用电喷雾检测器(HPLC-CAD) starting material of 6-ethylchenodeoxycholic acid related substances HPLC-CAD
  • 相关文献

参考文献3

二级参考文献21

  • 1叶磊,曹进,徐燕,王义明,罗国安.胆酸类成分HPLC/ELSD单一标准品替代法含量测定研究[J].中成药,2004,26(9):750-753. 被引量:15
  • 2王丽影,高昕,佟子林,王喜军.熊胆的化学成分、药理作用及临床研究概况[J].中医药信息,2005,22(4):30-33. 被引量:29
  • 3丁敏,叶炼,王猛,邵勇.高效液相色谱-串联质谱法同时测定血清中游离和结合型胆汁酸[J].分析化学,2007,35(10):1506-1508. 被引量:17
  • 4Ribera PE, Curran A. Current role of tenofovir in clinical medi- cine [ J ]. Enferm Infecc Microbiol Clin,2008,26 (Suppl 8 ) :45.
  • 5Novoa SR, Iabarga P, Sofiano V. Pharmacogenetics of tenofovir treatment[ J ]. Pharmacogenomics ,2009,10(10) : 1675.
  • 6Paredes R, Clotet B. Clinical management of HIV - 1 resistance [ J]. Antiviral Res ,2010,85 ( 1 ) :245.
  • 7DeChristoforo R, Penzak SR. Tenofovir: a nucleotide analogue re- verse - transcriptase inhibitor for treatment of HIV infection [ J ]. Am J Health Syst Pharm,2004 ,61 ( 1 ) :86.
  • 8Grim SA, Romanelli F. Tenofovir disoproxil fumarate [ J ]. Ann Pharmacother ,2003 ,37 ( 6 ) :849.
  • 9Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate : a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection[ J]. Clin Ther ,2002 ,24 (10) : 1515.
  • 10Lanier ER, Ptak RG, Lampert BM, et al. Development of hexade- cyloxypropyl tenofovir (CMX 157 ) for treatment of infection caused by wild - type and nucleoside/nucleotide - resistant HIV [ J ]. Antimicrob Agents Chemother,2010,54 ( 7 ) :2901.

共引文献46

同被引文献39

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部